OTCM
NONOF
Market cap195bUSD
Jun 17, Last price
44.01USD
1D
0.34%
1Q
19.98%
Jan 2017
146.55%
Name
Novo Nordisk A/S
Chart & Performance
P/E
12.62
P/S
4.39
EPS
22.73
Div Yield, %
3.30%
Shrs. gr., 5y
-1.27%
Rev. gr., 5y
18.94%
Revenues
290.40b
+25.03%
Net income
100.99b
+20.68%
CFO
120.97b
+11.07%
Dividend
Aug 15, 20240.517 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Novo Nordisk A/S, along with its affiliated companies, focuses on the discovery, production, and global sale of pharmaceutical goods. Its market presence extends across Europe, the Middle East, Africa, North America, and various Asian territories, including Mainland China, Hong Kong, and Taiwan. The company's activities are divided into two main categories: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division offers therapeutic solutions for conditions such as diabetes, obesity, cardiovascular health, and other developing medical areas. Meanwhile, the Rare Disease division provides treatments for unusual blood conditions, uncommon endocrine disorders, and hormone replacement therapies. Beyond its drug portfolio, Novo Nordisk also manufactures medical devices like insulin pens, growth hormone pens, and injection needles. Furthermore, it develops intelligent tools for diabetes management, including advanced smart insulin pens and the Dose Check application, designed to assist with insulin dosage guidance. The company holds a cooperative agreement with Aspen Pharmaceuticals for the manufacturing of insulin products. Novo Nordisk A/S was founded in 1923 and its corporate headquarters are located in Bagsvaerd, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||